Appendix 4E and Preliminary Final Report

Aug 28, 2026 at 2:07 AM EDT · Issued by Radiopharm Theranostics Limited via ASX

Filed with ASX · Aug 28, 2026 at 2:07 AM EDT

On 6ix: 6ix.com/news/appendix-4e-and-preliminary-final-report-74

RAD RADIOPHARM THERANOSTICS Preliminary Final Report : Year Ended 30 June 20 2 6 Radiopharm Theranostics Limited Appendix 4E Preliminary final report 1. Company details Name of entity: Radiopharm Theranostics Limited ABN: 57 647 877 889 Reporting period: For the...

View Attachment

6ix hasn’t read this filing yet.

Radiopharm Theranostics Limited on 6ix

Earlier from Radiopharm Theranostics

Change of Director's Interest Notices x 4Aug 27
Radiopharm Theranostics Doses First Patient in Second Cohort of Phase 1/2a Clinical Trial of BetaBart (RV-01) in B7-H3 Expressing Solid TumorsAug 26
RAD Doses First Patient in Second Cohort of BetaBart (RV-01)Aug 25
Ceasing to be a substantial holderAug 24
Radiopharm Theranostics Receives Positive Recommendation from Data Safety and Monitoring Committee to Advance to Cohort 4 in 177Lu-RAD202 Phase 1 HEAT Clinical TrialAug 20

Later from Radiopharm Theranostics

RAD Announces Positive Data from RAD301 P1 Imaging TrialSep 8
Radiopharm Theranostics Announces Positive Data from the Phase 1 Imaging Trial of RAD301 in Patients with Pancreatic Ductal AdenocarcinomaSep 9
Results of MeetingSep 10
RAD oral presentation at SNO26 on RAD101 Phase IIb dataSep 13
Radiopharm Theranostics Selected for Late-Breaking Oral Presentation of Positive Data from Interim Analysis of U.S. Phase 2b Imaging Trial of RAD101 at 2026 Society of Neuro-Oncology Annual MeetingSep 14

All Radiopharm Theranostics news releases

Follow Radiopharm Theranostics into a list and get an email when it puts out news.

Follow Radiopharm Theranostics